HomeCompareADDXF vs QSR

ADDXF vs QSR: Dividend Comparison 2026

ADDXF yields 202.02% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADDXF wins by $126.50M in total portfolio value
10 years
ADDXF
ADDXF
● Live price
202.02%
Share price
$0.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$126.53M
Annual income
$64,106,411.82
Full ADDXF calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — ADDXF vs QSR

📍 ADDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADDXFQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADDXF + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADDXF pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADDXF
Annual income on $10K today (after 15% tax)
$17,171.72/yr
After 10yr DRIP, annual income (after tax)
$54,490,450.05/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, ADDXF beats the other by $54,490,120.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADDXF + QSR for your $10,000?

ADDXF: 50%QSR: 50%
100% QSR50/50100% ADDXF
Portfolio after 10yr
$63.28M
Annual income
$32,053,399.85/yr
Blended yield
50.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

ADDXF
No analyst data
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADDXF buys
0
QSR buys
0
No recent congressional trades found for ADDXF or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADDXFQSR
Forward yield202.02%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$126.53M$24.7K
Annual income after 10y$64,106,411.82$387.88
Total dividends collected$119.31M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: ADDXF vs QSR ($10,000, DRIP)

YearADDXF PortfolioADDXF Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$30,902$20,202.02$11,038$337.57+$19.9KADDXF
2$91,409$58,344.23$12,156$345.43+$79.3KADDXF
3$259,102$161,293.94$13,359$352.69+$245.7KADDXF
4$704,521$427,281.62$14,654$359.36+$689.9KADDXF
5$1,839,646$1,085,809.10$16,045$365.45+$1.82MADDXF
6$4,618,204$2,649,782.60$17,539$370.97+$4.60MADDXF
7$11,158,255$6,216,776.60$19,143$375.96+$11.14MADDXF
8$25,977,314$14,037,980.69$20,863$380.42+$25.96MADDXF
9$58,339,227$30,543,501.04$22,708$384.39+$58.32MADDXF
10$126,529,384$64,106,411.82$24,685$387.88+$126.50MADDXF

ADDXF vs QSR: Complete Analysis 2026

ADDXFStock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Full ADDXF Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this ADDXF vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADDXF vs SCHDADDXF vs JEPIADDXF vs OADDXF vs KOADDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.